GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204–22.

Article  Google Scholar 

Torres A, Cilloniz C, Niederman MS, et al. Pneumonia Nat Rev Dis Primers. 2021;7(1):25. https://doi.org/10.1038/s41572-021-00259-0

Article  PubMed  Google Scholar 

Ferrer M, Travierso C, Cilloniz C, et al. Severe community-acquired pneumonia: characteristics and prognostic factors in ventilated and nonventilated patients. PLoS ONE. 2018;13(1):e0191721.

Article  PubMed  PubMed Central  Google Scholar 

Cavallazzi R, Furmanek S, Arnold FW, et al. The burden of community-acquired pneumonia requiring admission to ICU in the United States. Chest. 2020;158(3):1008–16.

Article  PubMed  PubMed Central  Google Scholar 

Martin-Loeches I, Torres A, Nagavci B, et al. ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia. Intensive Care Med. 2023;49(6):615–32.

Article  PubMed  PubMed Central  Google Scholar 

Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45–67.

Article  PubMed  PubMed Central  Google Scholar 

Fatima Z, Jayaratne P, Arrabi A, et al. Macrolide resistance and P1 cytadhesin genotyping of Mycoplasma pneumoniae during outbreak, Canada, 2024–2025. Emerg Infect Dis. 2025;31(12):2316–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Waites KB, Xiao L, Liu Y, Balish MF, Atkinson TP. Mycoplasma pneumoniae from the respiratory tract and beyond. Clin Microbiol Rev. 2017;30(3):747–809.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bidell MR, Lodise TP. Fluoroquinolone-associated tendinopathy: does levofloxacin pose the greatest risk? Pharmacotherapy. 2016;36(6):679–93.

Article  PubMed  Google Scholar 

Gorelik E, Masarwa R, Perlman A, Rotshild V, Muszkat M, Matok I. Fluoroquinolones and cardiovascular risk: a systematic review, meta-analysis and network meta-analysis. Drug Saf. 2019;42(4):529–38.

Article  CAS  PubMed  Google Scholar 

Bhavnani SM, Hammel JP, Lakota EA, et al. Pharmacokinetic-pharmacodynamic target attainment analyses evaluating omadacycline dosing regimens for the treatment of patients with community-acquired bacterial pneumonia arising from Streptococcus pneumoniae and Haemophilus influenzae. Antimicrob Agents Chemother. 2023;67(4):e0221321.

Article  PubMed  PubMed Central  Google Scholar 

Villano S, Steenbergen J, Loh E. Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections. Future Microbiol. 2016;11(14):1421–34.

Article  CAS  PubMed  Google Scholar 

Pfaller MA, Huband MD, Shortridge D, Flamm RK. Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: report from the SENTRY Antimicrobial Surveillance Program, 2016 to 2018. Antimicrob Agents Chemother. 2020;64(5):e02488–19.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pfaller MA, Rhomberg PR, Huband MD, Flamm RK. Activities of omadacycline and comparator agents against Staphylococcus aureus isolates from a surveillance program conducted in North America and Europe. Antimicrob Agents Chemother. 2017;61(3):e02411–16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

US Food and Drug Administration. NUZYRA (omadacycline). 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209816\_209817lbl.pdf

Stets R, Popescu M, Gonong JR, et al. Omadacycline for Community-Acquired Bacterial Pneumonia. N Engl J Med. 2019;380(6):517–27.

Article  CAS  PubMed  Google Scholar 

Torres A, Garrity-Ryan L, Kirsch C, et al. Omadacycline vs moxifloxacin in adults with community-acquired bacterial pneumonia. Int J Infect Dis. 2021;104:501–9.

Article  CAS  PubMed  Google Scholar 

Chen YJ, Gao SY, Fu J et al. The efficacy and safety of omadacycline in treating acute bacterial infections: a meta-analysis of randomized controlled trials. Expert Opin Drug Saf 2025 Feb 16:1–11.

Hróbjartsson A, Boutron I, Hopewell S, et al. SPIRIT 2025 explanation and elaboration: updated guideline for protocols of randomised trials. BMJ. 2025;389:e081660.

Article  PubMed  PubMed Central  Google Scholar 

Hopewell S, Chan AW, Collins GS, et al. CONSORT 2025 statement: updated guideline for reporting randomised trials. BMJ. 2025;389:e081123.

Article  PubMed  PubMed Central  Google Scholar 

Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163:1730–54.

Article  CAS  PubMed  Google Scholar 

Ramirez JA, Musher DM, Evans SE, et al. Treatment of Community-Acquired Pneumonia in Immunocompromised Adults: A Consensus Statement Regarding Initial Strategies. Chest. 2020;158(5):1896–911.

Article  PubMed  PubMed Central  Google Scholar 

Liu YN, Zhang YF, Xu Q, et al. Infection and co-infection patterns of community-acquired pneumonia in patients of different ages in China from 2009 to 2020: a national surveillance study. Lancet Microbe. 2023;4(5):e330–9.

Article  PubMed  PubMed Central  Google Scholar 

Zhang LL, Xiao Y, Zhang GL, et al. Identification of priority pathogens for aetiological diagnosis in adults with community-acquired pneumonia in China: a multicentre prospective study. BMC Infect Dis. 2023;23(1):231.

Article  PubMed  PubMed Central  Google Scholar 

Nie XM, Li YS, Yang ZW, et al. Initial empiric antibiotic therapy for community-acquired pneumonia in Chinese hospitals. Clin Microbiol Infect. 2018;24(6):658. e1-658.e6.

Article  Google Scholar 

Fan GH, Zhou YC, Zhou F, et al. The mortality and years of life lost for community-acquired pneumonia before and during COVID-19 pandemic in China. Lancet Reg Health West Pac. 2023;42:100968.

PubMed  PubMed Central  Google Scholar 

Simonetti AF, Garcia-Vidal C, Viasus D, et al. Declining mortality among hospitalized patients with community-acquired pneumonia. Clin Microbiol Infect. 2016;22(6):567. e1-567.e7.

Article  Google Scholar 

Honeyman L, Ismail M, Nelson ML, et al. Structure-activity relationship of the aminomethylcyclines and the discovery of omadacycline. Antimicrob Agents Chemother. 2015;59(11):7044–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pfaller MA, Huband MD, Shortridge D, et al. Surveillance of omadacycline activity tested against clinical isolates from the USA: report from the SENTRY antimicrobial surveillance program, 2019. J Glob Antimicrob Resist. 2021;27:337–51.

Article  CAS  PubMed  Google Scholar 

File TM Jr, Ramirez JA, Wilde AM. New Perspectives on Antimicrobial Agents: Omadacycline for community-acquired pneumonia, skin and soft tissue infections, and nontuberculous mycobacteria (focus on M. abscessus). Antimicrob Agents Chemother. 2025;69(2):e0108724.

Article  PubMed  PubMed Central  Google Scholar 

Paratek Pharmaceuticals. Paratek pharmaceuticals announces positive top-line efficacy and safety data from post-marketing study of NUZYRA (omadacycline) for patients with moderate to severe community-acquired bacterial pneumonia. 2024. Available from: https://www.globenewswire.com/news-release/2024/ 07/18/2915177/0/en/Paratek-Pharmaceuticals-Announces-Positive-Top-line-Efficacy-and-Safety-Data-from-Post-Marketing-Study-of-NUZYRA-omadacycline-for-Patients-with-Moderate-to-Severe-Community-Acquire.html

Li JL, Liu LS, Zhang H, et al. Severe problem of macrolides resistance to common pathogens in China. Front Cell Infect Microbiol. 2023;13:1181633.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cai FQ, Li JL, Liang WJ, et al. Effectiveness and safety of tetracyclines and quinolones in people with Mycoplasma pneumonia: a systematic review and network meta-analysis. EClinicalMedicine. 2024;71:102589.

Article  PubMed  PubMed Central